{"name":"Quanterix Corporation","slug":"quanterix","ticker":"QTRX","exchange":"NASDAQ","domain":"quanterix.com","description":"Quanterix Corporation, a life sciences company in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, the company offers contract research and clinical laboratory testing services, including research and clinical trial testing, and lucent diagnostic services. The company primarily operates in the areas of neurology, oncology and immunology, and inflammation. It sells its products for the life science resear","hq":"Billerica, MA","founded":0,"employees":"450","ceo":"Masoud Toloue","sector":"Life Sciences Tools & Diagnostics","stockPrice":2.9,"stockChange":0.02,"stockChangePercent":0.69,"marketCap":"$136M","metrics":{"revenue":144979008,"revenueGrowth":20.1,"grossMargin":45.3,"rdSpend":0,"netIncome":-104187000,"cash":99265000,"dividendYield":0,"peRatio":-2.1,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Quanterix Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Quanterix reported revenue of $34.4 million for the fourth quarter of 2023, a 24% increase from the same period in 2022.","drugName":"","sentiment":"positive"},{"date":"2023-11-15","type":"deal","headline":"Quanterix Announces Collaboration with Biogen to Develop Diagnostic Tests for Neurodegenerative Diseases","summary":"Quanterix has entered into a collaboration with Biogen to develop and commercialize diagnostic tests for neurodegenerative diseases using Quanterix's Simoa platform.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-01-10","type":"pipeline","source":"simplywall.st","summary":"Market Still Lacking Some Conviction On Quanterix Corporation (NASDAQ:QTRX) - simplywall.st","headline":"Market Still Lacking Some Conviction On Quanterix Corporation (NASDAQ:QTRX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwJBVV95cUxOaUZwb2h4YlJVT0dLS2gzbTdsZ0hsSWoyb0Y1czU4WVpDMlBVbHlxSWhpdm44RFpUVloxc05tb202dkFWWS1QVkU4Qy04SFpidFZkSkh0RTh2ZXI0RXNUZ1hsT0pSSlJlUDVKS3hCOVQ5TGRQeHdfbnV3UnlQSkEwWGE4aVMtUnpoOHMtQVMzaHZxdHlETXFER2Q3a3g4SlNlSU5XVnNUUW5zdlR6aFVzWVg5dElrdmNsT3FVbmJvNnRXUWxoZGxLWVJCbXBSV2V3VFNnQVhGeGxadjZYQnpiSTR5eldacVVlLXNzWVZYOUg5VTdMTVZzOHZLV2lMRDl3S1FZdUhoemYzQ3RGVWdB?oc=5","date":"2026-01-09","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: Quanterix (QTRX), Indivior (INDV) and GeneDx Holdings (WGS) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: Quanterix (QTRX), Indivior (INDV) and GeneDx Holdings (WGS)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE03SHFQMG1MeHg2aGc2MjNmaWNiX01FOUdTTTdhMExRX044dmNKZ2NQVXUxMjZrcUJRSDZlWVhZZnUtdzdIdks3cmFIQUtMc0dadDlVNEZrZHJMaHBHeVlVaVFQdHdJQlpQcHhUc1k5YTN5UjE3b0ZFUmZqamVLQQ?oc=5","date":"2025-11-10","type":"earnings","source":"Yahoo Finance","summary":"Quanterix Corp (QTRX) Q3 2025 Earnings Call Highlights: Navigating Challenges with Strategic ... - Yahoo Finance","headline":"Quanterix Corp (QTRX) Q3 2025 Earnings Call Highlights: Navigating Challenges with Strategic ...","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-31","type":"pipeline","source":"simplywall.st","summary":"Insiders' US$2.89m Investments In Red Following Quanterix's US$40m Dip In Market Value - simplywall.st","headline":"Insiders' US$2.89m Investments In Red Following Quanterix's US$40m Dip In Market Value","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxNdG4tTmpOU2dsNGM4cTdoTUpXbWdpRUdwLUpoekcycmJaaWxzSkVsTXRTajNiQ0twSnlQeUJIczZ6TWY0Tzc1ekFMNkcwVElkdUZTb2dXc0FTcjc0bXJNNHNla3FtcDN6VUd3ZEsxWENhY0hMaU11TmU2ekdjSFYzQkk4RnZyQldQMzhZUktTNHZGNTlxQUhnZHJYZXpsNmpnbkdmeThjV0RIMkl0WWlZazFFLTBJRVhZOFZEMGJXYjlHbUJVNnVUQV9FOWR4YWhJUFAwMkNmVXFmN2_SAeABQVVfeXFMTUhpaUlJNGE5cXEtaUF2NV9FMUNERTBfX1BhcFJab1pKY3p5QkNDSFZNQlN2QVYtaHp5ZE9yV20tc1pIN2N0RGctNHNGMS1Lc1hMTHZKUVBfVWZUVXlWZjl3MEZabE1RY3M1Rnpxd0ZZLXJPeUIyUjU2QlN3c25oTVJQWXZ0M1N3OXNmSzJyc2RfdlhLaURSQTZXeWtZeXo1dkhaYXJUQjRUcVVQVlNuUmwtbFlCanFudElGVXZoR2l6S2xuS1hZTGdaMDMtU1lsYU9ISGE1c2d1Sk45dzA2MDU?oc=5","date":"2025-10-04","type":"pipeline","source":"simplywall.st","summary":"After losing 49% in the past year, Quanterix Corporation (NASDAQ:QTRX) institutional owners must be relieved by the recent gain - simplywall.st","headline":"After losing 49% in the past year, Quanterix Corporation (NASDAQ:QTRX) institutional owners must be relieved by the rece","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-08-10","type":"earnings","source":"simplywall.st","summary":"Quanterix Corporation (NASDAQ:QTRX) Just Released Its Second-Quarter Earnings: Here's What Analysts Think - simplywall.st","headline":"Quanterix Corporation (NASDAQ:QTRX) Just Released Its Second-Quarter Earnings: Here's What Analysts Think","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxOMzRLc3JFZXc1T05FWnU1OW1weFdWcmNIdndUclowUDJVN1JtbXY4UWZCZzhxeEJ0azY2Rm9TSmNMeUZOVFVXZUlIYm0xZ2pJLVZ3bkxFY3dxWjJJeW5aMXVQckFuYmlyX3lhSXJaTDBiTmJDVENTU2hqVExjMlNUa2N1eVR4bC1wTmYweGFVLTI0dnNpeFhSU3BqeEtrcFpJOEtwWUlRdHQtQlVHejRramZWem5vbkV4Vk9PZi1RbWdMeXFnUUhPS1hCVERPYlhzSFow?oc=5","date":"2025-03-05","type":"pipeline","source":"citybiz","summary":"Ascend Advanced Therapies Appoints John Chiminski as Chair and Karen Flynn as Independent Director - citybiz","headline":"Ascend Advanced Therapies Appoints John Chiminski as Chair and Karen Flynn as Independent Director","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxNUWh0djdNRGFLNnVRaThxN2JObHpndTdVU1JFQXVZOEx3RmdJRXdXZmpWZGxZR01jQ0d5eVhVWS1zYk5WQXRYbWVvekRGMEpmcGhTYndYWmF6QWlMV0V4ZGptRjdXOFE5d1lxZ25DOVc5NVBUSklSdm92Wk9Fdk5VSGZzb1ppQVBJcUdXYjdRaTVJdUtvZ1JIM01TVUs1UXh2R2VZWjl4b1FfcEN6ZUMzZ1hhT0tMLTdNN1gyZWxRWGlSMllXWEx3cVhhYzRPcVhtX0tiTC1DVGhDal9yWWc3UXFYN1psS0pCMXpKZWItM2IzRmstOWdVVHNMWjVjUQ?oc=5","date":"2019-05-29","type":"regulatory","source":"BioSpace","summary":"Quanterix Expands Headquarters to New, State-of-the-Art Facility in Billerica, Mass. as Demand Continues to Grow for its Disruptive Simoa Platforms - BioSpace","headline":"Quanterix Expands Headquarters to New, State-of-the-Art Facility in Billerica, Mass. as Demand Continues to Grow for its","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Thermo Fisher Scientific","Danaher Corporation","Bio-Rad Laboratories"],"therapeuticFocus":["Neurodegenerative Diseases","Oncology"],"financials":{"source":"yahoo_finance","revenue":138654000,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":138654000},{"period":"2024-12-31","value":135436000},{"period":"2023-12-31","value":121139000},{"period":"2022-12-31","value":104952000}],"grossProfit":64716000,"grossProfitHistory":[{"period":"2025-12-31","value":64716000},{"period":"2024-12-31","value":81119000},{"period":"2023-12-31","value":72995000},{"period":"2022-12-31","value":44793000}],"rdSpend":35922000,"rdSpendHistory":[{"period":"2025-12-31","value":35922000},{"period":"2024-12-31","value":31082000},{"period":"2023-12-31","value":26064000},{"period":"2022-12-31","value":26809000}],"sgaSpend":138852000,"operatingIncome":-109815000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-109815000},{"period":"2024-12-31","value":-52616000},{"period":"2023-12-31","value":-44663000},{"period":"2022-12-31","value":-74708000}],"netIncome":-107150000,"netIncomeHistory":[{"period":"2025-12-31","value":-107150000},{"period":"2024-12-31","value":-38531000},{"period":"2023-12-31","value":-28354000},{"period":"2022-12-31","value":-99574000}],"eps":-1,"epsHistory":[{"period":"2024-12-31","value":-1},{"period":"2023-12-31","value":-0.75},{"period":"2022-12-31","value":-2.61},{"period":"2021-12-31","value":-1.602444}],"cash":29839000,"cashHistory":[{"period":"2025-12-31","value":29839000},{"period":"2024-12-31","value":56709000},{"period":"2023-12-31","value":174422000},{"period":"2022-12-31","value":338740000}],"totalAssets":418766000,"totalLiabilities":123036000,"totalDebt":37239000,"equity":295730000,"operatingCashflow":-77236000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-77236000},{"period":"2024-12-31","value":-35164000},{"period":"2023-12-31","value":-18849000},{"period":"2022-12-31","value":-48611000}],"capex":-2612000,"capexHistory":[{"period":"2025-12-31","value":-2612000},{"period":"2024-12-31","value":-3368000},{"period":"2023-12-31","value":-3841000},{"period":"2022-12-31","value":-11614000}],"freeCashflow":-79848000,"dividendsPaid":null,"buybacks":null,"employees":450,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":35110000,"ebit":-23868000,"ebitda":-14561000,"period":"2025-12-31","revenue":43777000,"epsBasic":-0.49,"netIncome":-23117000,"rdExpense":8796000,"epsDiluted":-0.49,"grossProfit":19960000,"operatingIncome":-23868000},{"sga":39348000,"ebit":-30151000,"ebitda":-25570000,"period":"2025-09-30","revenue":40150000,"epsBasic":-0.73,"netIncome":-33517000,"rdExpense":8009000,"epsDiluted":-0.73,"grossProfit":17123000,"operatingIncome":-30151000},{"sga":31649000,"ebit":-29430000,"ebitda":-26581000,"period":"2025-06-30","revenue":24454000,"epsBasic":-0.77,"netIncome":-30013000,"rdExpense":9081000,"epsDiluted":-0.77,"grossProfit":11278000,"operatingIncome":-29430000},{"sga":32745000,"ebit":-26366000,"ebitda":-24178000,"period":"2025-03-31","revenue":30273000,"epsBasic":-0.53,"netIncome":-20504000,"rdExpense":10036000,"epsDiluted":-0.53,"grossProfit":16355000,"operatingIncome":-26366000},{"sga":28871000,"ebit":-14769000,"ebitda":-11153000,"period":"2024-12-31","revenue":34106000,"epsBasic":-0.3,"netIncome":-11628000,"rdExpense":8067000,"epsDiluted":-0.3,"grossProfit":21114000,"operatingIncome":-14769000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":2.9,"previousClose":2.88,"fiftyTwoWeekHigh":8.77,"fiftyTwoWeekLow":2.56,"fiftyTwoWeekRange":"2.56 - 8.77","fiftyDayAverage":3.76,"twoHundredDayAverage":5.39,"beta":1.15,"enterpriseValue":71736224,"forwardPE":-2.1,"priceToBook":0.46,"priceToSales":0.94,"enterpriseToRevenue":0.49,"enterpriseToEbitda":-1.13,"pegRatio":0,"ebitda":-63673000,"ebitdaMargin":-43.9,"freeCashflow":-21983500,"operatingCashflow":-81455000,"totalDebt":35336000,"debtToEquity":12.5,"currentRatio":3.72,"returnOnAssets":-13.4,"returnOnEquity":-34.8,"analystRating":"3.0 - Hold","recommendationKey":"hold","numberOfAnalysts":3,"targetMeanPrice":5.33,"targetHighPrice":7,"targetLowPrice":4,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":6.2,"institutionHeldPercent":87.4,"sharesOutstanding":47105981,"floatShares":36904710,"sharesShort":4598830,"shortRatio":4.59,"shortPercentOfFloat":9.8,"epsTrailing":-2.35,"epsForward":-1.36,"revenuePerShare":3.24,"bookValue":6.33,"officers":[{"age":63,"name":"Mr. William P.  Donnelly","title":"Executive Chair"},{"age":72,"name":"Dr. David R. Walt Ph.D.","title":"Co-Founder & Chairman of Scientific Advisory Board"},{"age":51,"name":"Ms. Vandana  Sriram CPA","title":"CFO & Treasurer"},{"age":59,"name":"Mr. Everett V. Cunningham","title":"President, CEO & Director"},{"age":61,"name":"Dr. Michael  Miller Ph.D.","title":"Chief Operating Officer"},{"age":null,"name":"Mr. Jerzy  Olejnik","title":"Chief Technology Officer"},{"age":null,"name":"Joshua  Young","title":"Head of Investor Relations"},{"age":64,"name":"Mr. Daniel S. Char J.D.","title":"Chief Legal Officer & Corporate Secretary"}],"industry":"Medical Devices","irWebsite":"","website":"https://www.quanterix.com","phone":"617 301 9400"}}